About this trial
The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.
Eligibility criteria
Qualifiers
18-59 years old
Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)
Confirmed HIV diagnosis
Current receipt of daily oral antiretroviral therapy (ART) medication
Disqualifiers
Acute brain infection (e.g., neurosyphilis, toxoplasmosis)
Acutely symptomatic bipolar I or psychotic disorder
Prescription for immunomodulatory medications or other immunotherapy
Any MRI contraindications
Trial design
Treatments tested in this trial
- ARTEMIS
- Contingency management for Antiretroviral (ARV) adherence
Treatment groups
Sponsors and collaborators
Wake Forest University Health Sciences
Lead sponsor
Florida International University
Collaborator
National Institutes of Health (NIH)
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator